Options Solutions LLC buys 1,805 shares of Bristol-Myers Squibb (NYSE:BMY)

Options Solutions LLC boosted its stake in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 13.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 14,909 shares of the biopharmaceutical company’s stock after acquiring an additional 1,805 shares during the period. Bristol-Myers Squibb accounts for about 0.8% of Options Solutions LLC’s holdings, making the stock its 28th largest position. Options Solutions LLC’s holdings in Bristol-Myers Squibb were worth $765,000 at the end of the most recent reporting period.

A number of other large investors have added to or reduced their stakes in the stock. Mizuho Markets Americas LLC acquired a new position in shares of Bristol-Myers Squibb in the third quarter valued at $82,405,000. Johnson Investment Counsel Inc. raised its stake in shares of Bristol-Myers Squibb by 0.7% during the 3rd quarter. Johnson Investment Counsel Inc. now owns 127,714 shares of the biopharmaceutical company’s stock worth $7,412,000 after purchasing an additional 852 shares in the last quarter. Excalibur Management Corp raised its stake in Bristol-Myers Squibb by 5.8% in the 3rd quarter. Excalibur Management Corp now owns 21,037 shares of the biopharmaceutical company’s stock worth $1,221,000 after acquiring an additional 1,161 shares. shares in the last quarter. Financial Engines Advisors LLC purchased a new position in shares of Bristol-Myers Squibb in the third quarter valued at $241,000. Finally, Rafferty Asset Management LLC raised its stake in shares of Bristol-Myers Squibb by 7.6% during the third quarter. Rafferty Asset Management LLC now owns 224,040 shares of the biopharmaceutical company’s stock worth $13,003,000 after purchasing an additional 15,770 shares during the last quarter. Institutional investors own 76.41% of the company’s shares.

Changes in Analyst Ratings

Several research analysts recently weighed in on the stock. Wells Fargo & Company lifted their target price on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research note on Thursday, April 18th. William Blair restated a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. StockNews.com upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Thursday, May 23rd. BMO Capital Markets reduced their target price on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research note on Friday, April 26th. Finally, Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Bristol-Myers Squibb presently has an average rating of “Hold” and an average price target of $60.00, according to MarketBeat.com.

Read our latest analysis of BMY

Bristol-Myers Squibb Stock Performance

Shares of Bristol-Myers Squibb stock opened at $41.20 on Friday. The company’s 50-day moving average price is $44.50 and its 200-day moving average price is $48.73. Bristol-Myers Squibb has a 12-month low of $39.91 and a 12-month high of $66.38. The company has a quick ratio of 0.99, a current ratio of 1.11, and a debt-to-equity ratio of 2.99. The company has a market cap of $83.52 billion, a PE ratio of -13.29, a price-to-earnings-growth ratio of 14.36 and a beta of 0.43.

Bristol-Myers Squibb (NYSE:BMY – Get Your Free Report ) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The firm had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $11.45 billion. During the same period in the previous year, the firm posted EPS of $2.05. The company’s quarterly revenue was up 4.7% year over year. On average, equities research analysts forecast that Bristol-Myers Squibb will post 0.59 EPS for the current fiscal year.

Bristol-Myers Squibb profile

(Free report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic and neuroscience. The company’s products include Eliquis for reducing the risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anticancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Featured stories

Want to see what other hedge funds BMY owns? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY – Free Report).

Get news and reviews for Bristol-Myers Squibb Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Bristol-Myers Squibb and related companies with MarketBeat.com’s FREE daily email newsletter.